Zacks Investment Research lowered shares of DBV Technologies S.A. (NASDAQ:DBVT) from a buy rating to a hold rating in a research note issued to investors on Thursday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
A number of other equities research analysts have also issued reports on the company. Morgan Stanley reissued an overweight rating on shares of DBV Technologies in a research note on Monday, July 10th. Deutsche Bank AG started coverage on DBV Technologies in a research note on Friday, June 23rd. They set a buy rating and a $46.00 price target for the company. ValuEngine lowered DBV Technologies from a hold rating to a sell rating in a research note on Friday, June 30th. Leerink Swann raised their price target on DBV Technologies from $54.00 to $60.00 and gave the stock an outperform rating in a research note on Friday, August 25th. Finally, HC Wainwright reissued a buy rating and set a $50.00 price target on shares of DBV Technologies in a research note on Thursday, July 6th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. DBV Technologies has a consensus rating of Buy and a consensus target price of $50.50.
DBV Technologies (NASDAQ:DBVT) opened at 43.26 on Thursday. The company’s 50 day moving average price is $44.12 and its 200-day moving average price is $37.74. DBV Technologies has a one year low of $31.87 and a one year high of $46.33. The company’s market cap is $1.99 billion.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Equities Focus and is owned by of Equities Focus. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.equitiesfocus.com/2017/09/17/dbv-technologies-s-a-dbvt-cut-to-hold-at-zacks-investment-research.html.
A number of hedge funds and other institutional investors have recently modified their holdings of DBVT. Janus Henderson Group PLC bought a new stake in DBV Technologies during the 2nd quarter valued at $90,724,000. Jennison Associates LLC raised its position in DBV Technologies by 86.4% during the 2nd quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock valued at $35,784,000 after purchasing an additional 464,341 shares in the last quarter. Alliancebernstein L.P. raised its position in DBV Technologies by 21.1% during the 1st quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock valued at $35,098,000 after purchasing an additional 173,798 shares in the last quarter. Morgan Stanley raised its position in DBV Technologies by 89.9% during the 1st quarter. Morgan Stanley now owns 249,988 shares of the company’s stock valued at $8,805,000 after purchasing an additional 118,317 shares in the last quarter. Finally, Marshall Wace North America L.P. bought a new stake in DBV Technologies during the 1st quarter valued at $3,566,000. 45.52% of the stock is owned by institutional investors and hedge funds.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Get a free copy of the Zacks research report on DBV Technologies (DBVT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.